Tuesday, February 25, 2014

FDA Safety Alert Issued for AndroGelTM and other Popular Prescription Testosterone Supplements

Levensten Law Firm Making AndroGelTM FDA Freedom of Information Act Documents Available to Public on Its Websites for Free

PHILADELPHIA, PA – February 18, 2014 - The Levensten Law Firm, P.C. of Philadelphia, PA announces that pursuant to a Freedom of Information Act request (FOIA), the Food and Drug Administration (FDA) produced thousands of documents to the firm regarding potential health risks associated with AndroGelTM, a prescription testosterone supplement marketed by AbbVie.
The FDA Adverse Event Reports contained in the production show that between the years of 2002-2013, there were approximately 44 pulmonary embolisms, 42 heart attacks, 18 cerebral vascular accidents, and 12 deaths, among other injuries, reported for patients taking AndroGel during that time period.

“We believe these reports are the tip of the iceberg,” said Scott Levensten, Esq., Principal, Levensten Law Firm. “It’s important that this information gets out to the public as quickly as possible, not only for the people who are currently on the medication, but for those who are considering it.”

On January 31, 2014, the FDA issued a Safety Alert that it’s reassessing the safety of AndroGelTM and other prescription testosterone products after two separate studies showed that these products may increase the cardiovascular risks in some men. Several additional studies are ongoing. The AndroGelTM label and medication guide do not currently warn of the risk of heart attack, stroke and death potentially associated with the medication.  Five AndroGelTM lawsuits were recently filed in federal court in the state of Illinois by patients who allege that they suffered cardiovascular injuries.

“Our firm anticipates that the absence of any warning, coupled with documents produced by the FDA and AbbVie, in the backdrop of the massive low testosterone marketing campaigns that are ongoing, will set the stage for a large mass tort AndroGelTM federal Multidistrict Litigation and consolidated state court litigation” continued Scott Levensten Esq.

The Levensten Law Firm is making the FDA FOIA documents, along with the AndroGelTM label, medication guide, and recent studies, available to the public at no charge on its websites www.levenstenlawfirm.com and www.Androgellawyers.com.

For more information concerning the risks of prescription Testosterone products, please contact Scott Levensten, Esq. at the Levensten Law Firm, by phone at 215-545-5600 or by email sdl@levenstenlawfirm.com.

About The Levensten Law Firm

The Levensten Law Firm, P.C., is among this Country's leading plaintiffs' mass tort litigation firms. Mr. Levensten has been committed to representing victims of defective drugs and medical devices in federal and state courts nationwide for nearly two decades. Mr. Levensten was named a Pennsylvania SuperLawyer for the past 10 years in a row for his achievements in the area of mass torts.  Additional information is available at http://www.levenstenlawfirm.com and http://www.androgellawyers.com, as well as on Twitter at http://www.twitter.com/pharmainjurylaw and on Google+ at http://www.google.com/+ScottLevensten.